Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms...

Newly Published Study Results Showed That Two Mealtime Insulin Dosing
Algorithms Were Effective for Patients with Type 2 Diabetes
Two Regimens Including Lantus(R) and Apidra(R) Resulted in Significant
Reductions in A1C in Patients with Type 2 Diabetes, Whatever the Algorithm
Used

BRIDGEWATER, N.J., July 22 /PRNewswire/ -- Results from the "Adjust to
Target in Type 2 Diabetes: Comparison of a Simple Algorithm to Carbohydrate
Counting for Adjustment of Mealtime Insulin Glulisine" study, were published
in the American Diabetes Association's (ADA) medical journal, Diabetes Care.
This study, using a basal-bolus insulin regimen with Lantus(R) (insulin
glargine [rDNA origin] injection) once daily (basal insulin) and rapid-acting
Apidra(R) (insulin glulisine [rDNA origin] injection) at mealtime (bolus
insulin) demonstrated significant reductions in postprandial blood glucose and
A1C using two different dosing algorithms.
The 24-week, multicenter, randomized, controlled study compared two
algorithms for adjusting mealtime insulin (Apidra(R)) in 273 intent-to-treat
patients with type 2 diabetes. Apidra(R) and Lantus(R) were adjusted weekly in
both groups based on the previous week's self-monitored blood glucose (SMBG)
results. One group, the "Simplified Algorithm" group, was provided set doses
of Apidra(R) to take before each meal. The second group, the "Carbohydrate
Counting" group, was provided an insulin-to-carbohydrate ratio to use for each
meal and adjusted their Apidra(R) dose based on amount of carbohydrate
consumed. After 24 weeks, the percentage of patients who achieved A1C<7
percent -- the ADA's recommended target for blood sugar control -- while
following these two treatment algorithms were 73% and 69% (P=0.70),
respectively.
Average A1C levels at week 24 were 6.70 in the Simplified Algorithm group
and 6.54 percent in the Carb Counting group. The respective mean A1C changes
from baseline to 24 weeks were -1.46 percent and -1.59 percent (P=.24). A1C
<7.0 percent was achieved by 73 percent (Simplified Algorithm) and 69 percent
(Carb Counting) (P=.70); respective values for A1C <6.5 percent were 44.3
percent and 49.5 percent (P=.28). The Simplified Algorithm group had 53
episodes of severe hypoglycemia in 19 patients, and the Carb Counting group
had 37 episodes in 19 patients, leading to estimates of 0.89 and 0.67
event/patient-year for the two groups (P=0.58). SMBG < 50 mg/dL with symptoms
was slightly but statistically significantly more common in the Carb Counting
group than in the Simplified Algorithm group (8.0 vs. 4.9 events/patient-year,
P=0.02).
"A combination of basal and bolus insulin may be needed to achieve optimal
glucose control in type 2 diabetes patients," explained study author Richard
M. Bergenstal, MD, executive director, International Diabetes Center, Park
Nicollet Health Services, Minneapolis, MN. "The simplified algorithm
investigated in this study allowed patients to start with a fixed dose of
Apidra(R) and then effectively adjust to target based on premeal glucose
patterns, or to use carbohydrate counting, which involves a mathematical
formula that helps patients match the size of their mealtime insulin dose with
the amount of carbohydrates they eat. Having two effective options for
managing mealtime insulin doses may increase patients' and clinicians'
willingness to initiate basal-bolus therapy."
Throughout the study, SMBG levels were recorded before meals and at
bedtime each day, as well as a 7-point blood glucose profile at weeks 2, 6,
12, 18, and 24 (endpoint). Blood glucose values at each visit declined in both
arms, and the within-group change from baseline was statistically significant
over all daily time points and study visits. By the study's conclusion, both
arms significantly improved fasting plasma glucose (FPG) levels as well, with
averages of 112.0 mg/dl in the Simplified Algorithm group and 101.8 mg/dl in
the Carb Counting group (P<0.0001 for both groups).
"Type 2 diabetes is a progressive disease that requires treatment
adjustments to help manage the potential risks that come with prolonged
hyperglycemia," said Dr. Bergenstal. "The Adjust to Target trial demonstrated
that basal-bolus insulin therapy may be an effective option for the many
people with type 2 diabetes who are not achieving glycemic targets with their
current insulin regimen."
About the Trial
Study participants were 28-71 years old, had type 2 diabetes for greater
than or equal to 6 months and mean +/- SD A1C values of 8.1 +/- 0.9%
(Simplified Algorithm) and 8.3 +/- 0.9% (Carb Counting Algorithm) at
screening. They had taken greater than or equal to 2 insulin injections/day
(36 percent on 2 injections, 64 percent on more than 2 injections) +/-
metformin (one-third were on metformin), for greater than or equal to 3 months
before study entry. Upon entry into the study, 37 percent were using Lantus(R)
and at least one injection of a rapid-acting insulin analog, 36 percent were
using a pre-mixed insulin and the remainder were on a combination of various
other diabetes treatment regimens.
About Diabetes
Diabetes is a chronic, widespread condition in which the body does not
produce or properly use insulin -- the hormone needed to transport glucose
(sugar) from the blood into the cells of the body for energy. More than 230
million people worldwide are living with the disease and this number is
expected to rise to a staggering 350 million within 20 years. It is estimated
more than 20 million Americans have diabetes, including an estimated 6.2
million who remain undiagnosed.
At the same time, more than 40 percent of those diagnosed are not
achieving the blood sugar control target of A1C <7 percent recommended by the
American Diabetes Association (ADA). The A1C test measures average blood
glucose levels over a two- to three-month period.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
U.S. Media Contacts:
Carrie Melia
Carrie.Melia@sanofi-aventis.com
908-981-6486

US.GLA.08.06.085

SOURCE sanofi-aventis

Carrie Melia of sanofi-aventis, +1-908-981-6486,
Carrie.Melia@sanofi-aventis.com